{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:57:03Z","timestamp":1792036623139,"version":"4.4.0"},"reference-count":117,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T00:00:00Z","timestamp":1522972800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["F 5\/4\/150\/5"],"award-info":[{"award-number":["F 5\/4\/150\/5"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2018.00049","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T00:52:33Z","timestamp":1522975953000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":168,"title":["Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma"],"prefix":"10.3389","volume":"5","author":[{"given":"Florence","family":"Roufosse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,4,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3389\/fmed.2017.00115","article-title":"Transcription factors in eosinophil development and as therapeutic targets","volume":"4","author":"Fulkerson","year":"2017","journal-title":"Front Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1084\/jem.20020656","article-title":"Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo","volume":"195","author":"Yu","year":"2002","journal-title":"J Exp Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1126\/science.1099472","article-title":"Defining a link with asthma in mice congenitally deficient in eosinophils","volume":"305","author":"Lee","year":"2004","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/j.1365-2222.2011.03854.x","article-title":"Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor","volume":"42","author":"Molfino","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"B5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1084\/jem.172.5.1425","article-title":"Eosinophilia in transgenic mice expressing interleukin 5","volume":"172","author":"Dent","year":"1990","journal-title":"J Exp Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1074-7613(00)80294-0","article-title":"IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses","volume":"4","author":"Kopf","year":"1996","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1084\/jem.183.1.195","article-title":"Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model","volume":"183","author":"Foster","year":"1996","journal-title":"J Exp Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fmed.2017.00101","article-title":"Homeostatic eosinophils: characteristics and functions","volume":"4","author":"Marichal","year":"2017","journal-title":"Front Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1182\/blood-2014-10-607788","article-title":"Eosinophil-specific deletion of IkappaBalpha in mice reveals a critical role of NF-kappaB-induced Bcl-xL for inhibition of apoptosis","volume":"125","author":"Schwartz","year":"2015","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1189\/jlb.5BT0814-374R","article-title":"At the bench: understanding group 2 innate lymphoid cells in disease","volume":"97","author":"Doherty","year":"2015","journal-title":"J Leukoc Biol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jaci.2015.05.037","article-title":"Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia","volume":"137","author":"Smith","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.pharmthera.2016.10.016","article-title":"Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation","volume":"169","author":"Nixon","year":"2017","journal-title":"Pharmacol Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/ACI.0000000000000251","article-title":"Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs","volume":"16","author":"Varricchi","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s40265-015-0513-8","article-title":"Mepolizumab: first global approval","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.5414\/CP202446","article-title":"Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab","volume":"53","author":"Pouliquen","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil\u2019s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","article-title":"An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis","volume":"141","author":"Assa\u2019ad","year":"2011","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jaci.2008.02.033","article-title":"Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels","volume":"121","author":"Stein","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/cpdd.205","article-title":"Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin 5 monoclonal antibody, in healthy Japanese male subjects","volume":"5","author":"Tsukamoto","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1067\/mai.2003.1382","article-title":"Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics","volume":"111","author":"Menzies-Gow","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40265-016-0583-2","article-title":"Reslizumab: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jaci.2004.08.027","article-title":"Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700","volume":"114","author":"Kim","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/17425255.2017.1359253","article-title":"Pharmacokinetic\/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma","volume":"13","author":"Matera","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jaci.2010.04.005","article-title":"Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma","volume":"125","author":"Busse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/psp4.12160","article-title":"Population pharmacokinetics and pharmacodynamics of benralizumab in healthy volunteers and patients with asthma","volume":"6","author":"Wang","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","article-title":"Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia","volume":"132","author":"Laviolette","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.rmed.2016.01.003","article-title":"Reductions in eosinophil biomarkers by benralizumab in patients with asthma","volume":"111","author":"Pham","year":"2016","journal-title":"Respir Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ajem.2014.09.036","article-title":"A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma","volume":"33","author":"Nowak","year":"2015","journal-title":"Am J Emerg Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.4049\/jimmunol.170.11.5359","article-title":"Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression","volume":"170","author":"Gregory","year":"2003","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1067\/mai.2001.119149","article-title":"The trials and tribulations of IL-5, eosinophils, and allergic asthma","volume":"108","author":"O\u2019Byrne","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jaci.2011.05.032","article-title":"IL-5 receptor alpha levels in patients with marked eosinophilia or mastocytosis","volume":"128","author":"Wilson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","article-title":"Eosinophilic inflammation in asthma","volume":"323","author":"Bousquet","year":"1990","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/icb.1997.43","article-title":"Interleukin-5 and eosinophils induce airway damage and bronchial hyperreactivity during allergic airway inflammation in BALB\/c mice","volume":"75","author":"Hogan","year":"1997","journal-title":"Immunol Cell Biol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3389\/fmed.2017.00158","article-title":"Asthma endotypes and an overview of targeted therapy for asthma","volume":"4","author":"Svenningsen","year":"2017","journal-title":"Front Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1056\/NEJMoa031261","article-title":"Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis","volume":"349","author":"Plotz","year":"2003","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jaci.2003.10.049","article-title":"Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes","volume":"113","author":"Garrett","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40264-017-0522-5","article-title":"Targeting interleukin-5 or interleukin-5Ralpha: safety considerations","volume":"40","author":"Bagnasco","year":"2017","journal-title":"Drug Saf"},{"key":"B45","doi-asserted-by":"publisher","first-page":"201s11","DOI":"10.1126\/scitranslmed.3006800","article-title":"Power of rare diseases: found in translation","volume":"5","author":"Fishman","year":"2013","journal-title":"Sci Transl Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/nbt1114-1075","article-title":"Anti-IL-5 biologics carve out severe-asthma niche","volume":"32","author":"Dolgin","year":"2014","journal-title":"Nat Biotechnol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jaci.2006.09.007","article-title":"Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis","volume":"118","author":"Stein","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"key":"B49","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1056\/NEJMra1502863","article-title":"Eosinophilic esophagitis","volume":"373","author":"Furuta","year":"2015","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.4049\/jimmunol.168.5.2464","article-title":"IL-5 promotes eosinophil trafficking to the esophagus","volume":"168","author":"Mishra","year":"2002","journal-title":"J Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.gastro.2003.07.007","article-title":"Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism","volume":"125","author":"Mishra","year":"2003","journal-title":"Gastroenterology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001840","article-title":"Safety and efficacy of reslizumab for children and adolescents with eosinophilic esophagitis treated over nine years","author":"Markowitz","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B57","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/MPG.0b013e31817f0197","article-title":"Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis","volume":"48","author":"Pentiuk","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B58","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-pathol-012615-044241","article-title":"Mechanisms of disease of eosinophilic esophagitis","volume":"11","author":"Davis","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jaci.2013.02.042","article-title":"Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis","volume":"131","author":"Otani","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.jaci.2015.10.010","article-title":"Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis","volume":"136","author":"Bachert","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B61","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.4049\/jimmunol.158.8.3902","article-title":"Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia","volume":"158","author":"Simon","year":"1997","journal-title":"J Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2500\/ajra.2017.31.4412","article-title":"Monoclonal antibody therapy in sinonasal disease","volume":"31","author":"Chiarella","year":"2017","journal-title":"Am J Rhinol Allergy"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.jaip.2017.08.001","article-title":"Biologic agents for the treatment of hypereosinophilic syndromes","volume":"5","author":"Kuang","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B66","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3389\/fmed.2017.00216","article-title":"(A critical appraisal of) Classification of hypereosinophilic disorders","volume":"4","author":"Kahn","year":"2017","journal-title":"Front Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","article-title":"Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome","volume":"125","author":"Kim","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","article-title":"Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome","volume":"155","author":"Moosig","year":"2011","journal-title":"Ann Intern Med"},{"key":"B71","first-page":"S62","article-title":"Extended follow-up after stopping mepolizumab in relapsing\/refractory Churg-Strauss syndrome","volume":"30","author":"Herrmann","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"key":"B73","first-page":"A1365","article-title":"Observational experience describing the use of mepolizumab in patients with hypereosinophilic syndrome","volume":"191","author":"Duncan","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"B74","first-page":"317","article-title":"Hypereosinophilic syndrome presenting as an unusual triad of eosinophilia, severe thrombocytopenia, and diffuse arterial thromboses, with good response to mepolizumab","volume":"11","author":"Leon-Ferre","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-218992","article-title":"Therapeutic effect of anti-IL-5 on eosinophilic myocarditis with large pericardial effusion","author":"Song","year":"2017","journal-title":"BMJ Case Rep"},{"key":"B76","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jpeds.2009.01.058","article-title":"Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5","volume":"155","author":"Mehr","year":"2009","journal-title":"J Pediatr"},{"key":"B77","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.iac.2007.07.002","article-title":"Lymphocytic variant hypereosinophilic syndromes","volume":"27","author":"Roufosse","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"key":"B78","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1067\/mai.2002.127003","article-title":"High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome","volume":"110","author":"de Lavareille","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/MD.0000000000000088","article-title":"The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype","volume":"93","author":"Lef\u00e8vre","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/BOR.0000000000000015","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management","volume":"26","author":"Mahr","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.autrev.2014.12.004","article-title":"Churg-Strauss syndrome","volume":"14","author":"Greco","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/j.1398-9995.2012.02873.x","article-title":"Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome","volume":"67","author":"Khoury","year":"2012","journal-title":"Allergy"},{"key":"B84","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.autrev.2016.11.001","article-title":"Hypereosinophilia with asthma and systemic (non-vasculitic) manifestations: eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome?","volume":"16","author":"Lefevre","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B85","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaci.2009.10.014","article-title":"Sustained response to mepolizumab in refractory Churg-Strauss syndrome","volume":"125","author":"Kahn","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/all.13131","article-title":"Evidence for a role of eosinophils in blister formation in bullous pemphigoid","volume":"72","author":"de Graauw","year":"2017","journal-title":"Allergy"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/exd.13416","article-title":"Eosinophils as putative therapeutic targets in bullous pemphigoid","volume":"26","author":"Simon","year":"2017","journal-title":"Exp Dermatol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3389\/fmed.2017.00179","article-title":"New insights into drug reaction with eosinophilia and systemic symptoms pathophysiology","volume":"4","author":"Musette","year":"2017","journal-title":"Front Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.10.020","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome successfully treated with mepolizumab","author":"Ange","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/17474086.2016.1254036","article-title":"Clonal eosinophil and mast cell diseases: different in the same way?","volume":"9","author":"De Wilde","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fmed.2017.00103","article-title":"Bidirectional mast cell-eosinophil interactions in inflammatory disorders and cancer","volume":"4","author":"Galdiero","year":"2017","journal-title":"Front Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bcmd.2017.04.008","article-title":"Resolution of a steroid-resistant, hypereosinophilic immune diathesis with mepolizumab and concomitant amelioration of a mixed thrombotic microangiopathy","volume":"69","author":"Mulvey","year":"2018","journal-title":"Blood Cells Mol Dis"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jaip.2017.01.013","article-title":"Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis","volume":"5","author":"Altman","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B94","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0002-9343(03)00475-3","article-title":"Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib","volume":"115","author":"Koury","year":"2003","journal-title":"Am J Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1089\/mab.2016.0038","article-title":"Tolerance and efficacy with simultaneous use of two monoclonal antibodies for a patient with hypereosinophilic syndrome and ulcerative colitis","volume":"35","author":"Patel","year":"2016","journal-title":"Monoclon Antib Immunodiagn Immunother"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/j.1365-2133.2004.06239.x","article-title":"Angiolymphoid hyperplasia with eosinophilia treated with anti-interleukin-5 antibody (mepolizumab)","volume":"151","author":"Braun-Falco","year":"2004","journal-title":"Br J Dermatol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jaci.2007.03.043","article-title":"Eosinophils: singularly destructive effector cells or purveyors of immunoregulation?","volume":"119","author":"Jacobsen","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1183\/09031936.03.00027302","article-title":"Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions","volume":"21","author":"Buttner","year":"2003","journal-title":"Eur Respir J"},{"key":"B100","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/14740338.2017.1286327","article-title":"The safety of mepolizumab for the treatment of asthma","volume":"16","author":"Leung","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Ther"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e0166833","DOI":"10.1371\/journal.pone.0166833","article-title":"Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1182\/blood-2012-06-330845","article-title":"The expanding role(s) of eosinophils in health and disease","volume":"120","author":"Jacobsen","year":"2012","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/all.12169","article-title":"The consequences of not having eosinophils","volume":"68","author":"Gleich","year":"2013","journal-title":"Allergy"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"B106","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jaci.2010.04.029","article-title":"Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis","volume":"126","author":"Conus","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1164\/rccm.201611-2234OC","article-title":"Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma","volume":"196","author":"Kelly","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","article-title":"Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study","volume":"167","author":"Kips","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"B109","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.4049\/jimmunol.151.3.1235","article-title":"Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes","volume":"151","author":"Finkelman","year":"1993","journal-title":"J Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/1521-4141(200104)31:4<1087::AID-IMMU1087>3.0.CO;2-Q","article-title":"Neutralizing monoclonal antibodies can potentiate IL-5 signaling","volume":"31","author":"Zabeau","year":"2001","journal-title":"Eur J Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1056\/NEJMe1704402","article-title":"Targeting eosinophils in eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Djukanovic","year":"2017","journal-title":"N Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B113","first-page":"217","article-title":"Immunoelectrophoretic analysis in acrodermatitis chronica atrophicans","volume":"46","author":"Kraus","year":"1966","journal-title":"Acta Derm Venereol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13223-016-0174-5","article-title":"Airway autoimmune responses in severe eosinophilic asthma following low-dose mepolizumab therapy","volume":"13","author":"Mukherjee","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13223-017-0217-6","article-title":"Response to case report: airway autoimmune responses in severe eosinophilic asthma following low-dose mepolizumab therapy","volume":"13","author":"Pouliquen","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jaci.2013.11.026","article-title":"Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis","volume":"133","author":"Haldar","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/ped.2017.0779","article-title":"Adrenal insufficiency in pediatric eosinophilic esophagitis patients treated with swallowed topical steroids","volume":"30","author":"Hsu","year":"2017","journal-title":"Pediatr Allergy Immunol Pulmonol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmed.2018.00049\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T19:18:07Z","timestamp":1693595887000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmed.2018.00049\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,6]]},"references-count":117,"alternative-id":["10.3389\/fmed.2018.00049"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2018.00049","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,6]]},"article-number":"49"}}